DigiCon

According to you which are the top 3 important aspects of the Ominous Octet that is more prevalent in Indian diabetes patients? *

Beta cell dysfunction – impaired insulin secretion

Alpha cell dysfunction – impaired glucagon secretion

Increased hepatic glucose output

Impaired incretin effect

Insulin resistance

Decreased glucose uptake by skeletal muscles

Increased glucose reabsorption

Neurotransmitter defects

Please provide percentage of T2 Diabetes patients as per the gender from your clinical practice *

Male	%
Female	%
Others	%

At the time of first diagnosis of T2D, what percentage of patients fall in below HbA1c categories ? *

7-8%

8.1-9%

9.1-10%

>10%

Please provide HbA1c target or goals in following subgroup of patients with T2DM in your clinical practice? *

In patients with co-morbidities	%
In patients without co-morbidities	%
Above 75 years of age	%

At what HbA1c would you choose to initiate dual Oral Anti Diabetic (OAD) therapy? *

>7.5%

>8%

>8.5%

>9%

At what HbA1c would you choose to initiate triple OAD therapy *

>8%

>8.5%

>9%

>9.5%

Please provide percentage of following co-morbidities that you observe in your T2DM patients *

CAD	%
CKD	%
Obesity or overweight	%
Dyslipidemia	%
Heart Failure	%

What percentage of your T2D patients are on following therapies? *

Single OAD	%
Dual OAD	%
Triple OAD	%
> three OAD	%
Insulin + OAD	%

What is the percentage of following complications in your Type 2 Diabetes patients? *

Diabetic retinopathy	%
Diabetic neuropathy	%
Diabetic nephropathy	%

In your Type 2 diabetes patients – which agent (SU / DPP4i / SGLt2i / GLP-1) would you rate as the most suitable for the following parameters – (choose any one Oral Anti-Diabetic agent for each parameter) *

Advantage of cardiovascular outcomes –

Renal outcome benefits

Superior HbA1c control

Weight lowering

Overall safety

Tolerability

Ease of usage

In your Type 2 diabetes patients – which agent (SU / DPP4i / SGLt2i / GLP-1) would you rate as the most suitable for the following parameters – (choose any one Oral Anti-Diabetic agent for each parameter) *

Advantage of cardiovascular outcomes
Renal outcome benefits
Superior HbA1c control
Weight lowering
Overall safety
Tolerability
Ease of usage

What percentage of your diabetes patients are on GLP-1 RA? *

< 5%

6-10%

11-15%

12-20%

>21%

What is the probable reason for low adoption of GLP-1 RA apart from the cost of therapy? *

What percentage of your diabetes patients are on insulin? *

< 5%

6-20%

20-40%

40-50%

>50%

What percentage of your patients are on following types of Insulin? *

Human Insulins (fast acting and mixed)	%
Insulin analogues (newer insulin)	%
Insulin glargine	%

In your patients with diabetes and CKD what percentage of patients would be on newer non-steroidal MRA treatment? *

<5%

6-10%

11-15%

16-20%

NOT used so far

Usually in which stages of CKD, would you consider adding finerenone to treatment in type 2 diabetes patients? *

Early stages – I and II

Later stages – III and IV

Across stages – I to IV

Please provide percentage of overweight or obese T2DM patients who require medical management for weight reduction? *

<10%

10-25%

25-50%

>50%

Currently how many overweight and obese patients are on injectable GLP-1 treatment in your clinical practice? *

5%

6-10%

11-15%

>15%

Not using GLP-1 currently

Do you use CGM for your patients in your clinical practice? *

Yes

No

Q 19 : If yes how many patients do you consider for CGM in a month?

1-2

3-5

5-8

>10

What is the profile of patient in whom you will consider CGM? *

What percentage of Type 2 Diabetes patients are on Medical Nutrition therapy - MNT? *

1<5%

5-10%

10-25%

25-50%

>50%

What are the challenges for higher usage of Medical Nutrition therapy in your patients? *

High cost

Inconvenient to prepare

Taste issues – aftertaste etc

Multiple antidiabetic therapiesAny other suggestions

Which patient profile according to you would be ideal to receive Medical Nutrition therapy? *

Kindly elaborate

Which patient profile according to you would be ideal to receive GLP 1RA for T2DM? *

Kindly elaborate

Kindly provide your perspectives regarding Indian T2DM patients or Indian phenotype? *

Kindly provide your perspectives for low adoption of triple fixed dose combinations for T2DM management? *

Please provide benefits of Finerenone in diabetic kidney disease in your clinical practice? *

{{ $ActivityTypeName }}

Gathering perceptions on Type 2 diabetes mellitus landscape from prevalence to management (DM Landscape)